Saturday 17 October 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.38
0.03
−7.32%
Follow TNYA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 0.00 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (7.78) | (45.33) | |
P/B ratio |
— | — | 1.41 | 2.32 | |
Price to Tangible BV |
— | — | 1.41 | 2.32 | |
EV/Sales |
— | — | 0.00 | 0.00 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.07) | (1.58) | |
EV/FCF |
— | — | (1.06) | (1.58) | |
Quick Ratio |
4.26 | 6.51 | 5.45 | 4.12 | |
Current Ratio |
4.64 | 6.84 | 5.75 | 4.52 | |
Net Debt/EBITDA |
2.97 | 5.31 | 4.42 | 1.84 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.69 | 1.00 | 0.08 | |
Capex/Depreciation |
(0.01) | (0.04) | (0.01) | (0.09) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 6,596.89% | 1,495.77% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,420.89% | 487.03% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 976.00% | 153.24% | |
Graham Net Nets |
— | — | 0.45 | 0.38 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (68.12%) | (71.62%) | |
Free Cash Flow Yield |
— | — | (43.19%) | (32.66%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF per Share |
(0.10) | (0.09) | (0.09) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.10) | (0.09) | (0.09) | (0.02) | |
Cash per Share |
0.34 | 0.66 | 0.37 | 0.36 | |
Shareholders Equity per Share |
0.51 | 0.81 | 0.49 | 0.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.51 | 0.81 | 0.49 | 0.32 | |
Free Cash Flow |
(15.62) | (14.01) | (19.24) | (3.71) | |
Working Capital |
48.03 | 90.15 | 79.78 | 66.99 | |
Capital Expenditures |
(0.03) | (0.07) | (0.01) | (0.16) | |
Net Current Asset Value |
39.13 | 81.93 | 67.68 | 61.88 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.14 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.34 | 4.37 | 3.49 | 3.10 | |
Average Assets |
122.78 | 133.43 | 139.51 | 107.85 | |
Average Common Equity |
97.74 | 108.06 | 112.79 | 84.62 |
Columns are period end dates